Wipro has been recognized as a Leader in the 2025 Everest Group Pharmacovigilance (PV) Operations PEAK Matrix® Assessment. In this evaluation, Everest Group assessed approximately 29 PV operations providers listed on the Pharmacovigilance (PV) Operations PEAK Matrix® and identified Wipro as a Leader in this domain.
“Pharmacovigilance is becoming increasingly data-intensive and complex, driven by diverse global regulatory requirements and the rise of combination therapies. In response, enterprises are seeking partners that can blend deep scientific expertise with scalable, technology-driven solutions,” says Vandana Sharma, Practice Director at Everest Group.
“Wipro has distinguished itself through extensive pharmacovigilance services, particularly excelling in case processing and device complaint handling for MedTech clients. Its robust safety platform, TaloSafe, combined with strategic technology partnerships enhancing cognitive adverse event analysis, automated literature surveillance, and AI-based case intake solutions, positions it uniquely in the market. Clients have particularly valued Wipro’s competitive pricing, regional flexibility, and operational strength, which together have contributed to its recognition as a Leader in Everest Group’s Post-Approval Pharmacovigilance Operations PEAK Matrix® Assessment 2025.”